Manufacturing trials

Futura Medical PLC 25 April 2005 Press Release 25 April 2005 Futura Medical Plc CSD500 Manufacturing trials Futura Medical plc ('Futura' or 'the Company'), the AIM-listed pharmaceutical and medical device group that develops innovative products for the sexual healthcare market, today announces completion of initial manufacturing trials of its Condom Safety Device ('CSD500'). This manufacturing trial follows encouraging stability and compatibility results on the gel in laboratory studies and will generate essential data to confirm the laboratory data. This will facilitate the submission of an application to EU regulators for CSD500 marketing authorisation later in the year. CSD500 is a latex condom incorporating within its teat a gel to help healthy men maintain an erection throughout intercourse, thereby reducing the likelihood of condom slippage. James Barder, Chief Executive of Futura, said: 'This is an important step towards the completion of the dossier for CSD500.' For further information: Futura Medical plc James Barder, Chief Executive Tel: +44 (0) 1483 845 670 mail to: james.barder@futuramedical.co.uk www.futuramedical.co.uk Media enquiries: Abchurch Peter Curtain / Samantha Robbins Tel: +44 (0) 20 7398 7700 mailto: samantha.robbins@abchurch-group.com www.abchurch-group.com Notes to Editors: Futura Medical is an AIM-listed pharmaceutical drug and medical device group developing innovative products for sexual health. The Company is developing a portfolio of products with the intention of licensing their manufacture and distribution to major pharmaceutical and healthcare groups. Several agreements have been signed. Futura's primary focus is on Over the Counter ('OTC') products with particular appeal to men and women who are reluctant to discuss potentially embarrassing sexual matters with their doctors. The Company has three products in development and is in discussions to expand the pipeline. CSD500 is a latex condom incorporating within its teat a gel to help healthy men maintain an erection throughout intercourse, thereby reducing the likelihood of condom slippage. An exclusive agreement for worldwide distribution has been signed with SSL International plc, the maker of Durex(TM). FLD500, aimed primarily at female partners of male condom users, will help women maintain lubrication during intercourse, thereby reducing the risk of condom failure. SSL International plc holds an option for worldwide distribution rights. In trials, MED2002, a locally applied gel for erectile dysfunction ('ED'), has shown dramatically improved dermal absorption rates and a dose-ranging study is currently being conducted prior to commencement of a Phase III study in late 2005. Futura has entered into exclusive discussions with a major global pharmaceutical group for the worldwide development and marketing of MED2002. A trial to assess the safety of MED2002 in angina patients has already been successfully completed. Subject to regulatory approval the Company intends to recruit men suffering from ED with mild to moderate angina into the Phase III trial. Normal medications taken by angina patients prevent the use of available ED treatments such as Viagra(TM), Cialis(TM) and Levitra(TM). www.futuramedical.co.uk This information is provided by RNS The company news service from the London Stock Exchange